Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors

British Journal of Pharmacology

Volumn 125, Issue 7, 1998, Pages 1413-1420

  Watson, J ^a   Brough, S ^a   Coldwell, M C ^a   Gager, T ^a   Ho, M ^a   Hunter, A J ^a   Jerman, J ^a   Middlemiss, D N ^a   Riley, G J ^a   Brown, A M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT receptors; Cultured cell lines; Cytoplasmic Ca2+ ; Muscarinic receptor agonist; Radioligand binding; Rat brain; Xanomeline; 35S GTP S binding

Indexed keywords

ATROPINE; CALCIUM ION; CARBACHOL; FLUORESCENT DYE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HIMBACINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXOTREMORINE M; PIRENZEPINE; QUINUCLIDINYL BENZILATE; RECOMBINANT PROTEIN; SEROTONIN 1 RECEPTOR; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SULFUR 35; TRITIUM; XANOMELINE;

ANIMAL CELL; ARTICLE; BRAIN MEMBRANE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RECEPTOR AFFINITY;

EID: 7844250486     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702201     Document Type: Article

References (35)

1. BLANK, J.L., ROSS, A.H. & EXTON, J.H. (1991). Purification and characterisation of two G-proteins that activate the β1 isozyme of phosphoinositide-specific phospholipase C. J. Biol. Chem., 266, 18206-18216.
2. BODICK, N.C., OFFEN, W.W., LEVEY, A.I., CUTLER. N.R., GAUTHIER, S.G., SATLIN, A., SHANNON, H.E., TOLLEFSON, G.D., RASMUSSEN, K., BYMASTER, F.P., HURLEY, D.J., POTTER, W.Z. & PAUL, S.M. (1997a). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in Alzheimer's disease. Arch. Neural., 54, 465-473.
3. BODICK, N.C., OFFEN, W.W., SHANNON, H.E., SATTERWHITE, J., LUCAS, R., VANLIER, R. & PAUL, S.M. (1997b). The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioural symptoms of Alzheimer disease. Alzheimer disease and associated disorders, 11, S16-S22.
4. BOLDEN, C., CUSACK, B. & RICHELSON, E. (1991). Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther., 260, 576-580.
5. BOWEN, D.M. (1983). Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease. In: Banbury Report 15. ed. Katzman, R. pp. 219-232. Cold Spring Harbour.
6. BRANN, M.R., CONKLIN, B., DEAN, N.M., COLLINS, R.M., BONNER, T.I. & BUCKLEY, N.J. (1988). Cloned muscarinic receptors can couple to different G-proteins and second messengers. Soc. Neurosci. Abstr., 14, 600.
7. BROWN, F., CAMPBELL, W., CLARK, M., GRAVES, D., HADLEY, M., HATCHER, J., MCARTHUR, R., RILEY, G. & SEMPLE, J. (1988). Variations of muscarinic activities of oxotremorine analogues. Drug Dev. Res., 14, 343-347.
8. 1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J. Pharm. Exp. Ther., 269, 282-289.
9. CHENG, Y.C. & PRUSSOF, W.H. (1973). Relationship between inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol., 92, 881-894.
10. 1 receptors by xanomeline. Eur. J. Pharm., 334, R3-R4.
11. CLAGUE, R.U., EGLEN, R.M., STRACHAN, A.C. & WHITING, R.L. (1985). Action of agonists and antagonists at muscarinic receptors present on ileum and atria in vitro. Br. J. Pharmacol., 86, 163-170.
12. COYLE, J.T., PRICE, D.L. & DELONG, M.R. (1983). Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation. Science, 219, 1184-1190.
13. DORJE, F., WESS, J., LAMBRECHT, G., TACKE, R., MUTSCHLER, E. & BRANN, M.R. (1990). Antagonist binding profiles of five cloned human muscarinic receptor subtypes. Jr. Pharmacol and Exp. Ther., 256, 727-733.
14. 1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster overy-m1 cells. Life Sci., 57, 1183-1190.
15. FLETCHER, A., FORSTER, E.A., BILL, D.J., BROWN, G., CLIFFE, I.A., HARTLEY, J.E., JONES, D.E., McLENACHAN, A., STANHOPE, K.J., CRITCHLEY, D.J.P., CHILDS, K.J., MIDDLEFELL, V.C., LANFUMEY, L., CORRADETTI, R., LAPORTE, A.-M., GOZLAN, H., HAMON, M. & DOURISH, C.T. (1996). Electrophysiological biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav. Biochem. Res., 73, 337-353.
16. 3 muscarinic receptor subtypes in primate brain. Synapse., 14, 283-296.
17. FREEDMAN, S.B., HARTLEY, E.A. & IVERSEN, L.L. (1988). Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: the NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors. Br. J. Pharmacol., 93, 437-445.
18. 2c,2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol., 117, 427-434.
19. 2c receptor antagonist. Neuropharmacol., 36, 609-620.
20. 35S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies. Br. J. Pharmacol., 109, 1120-1127.
21. 4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol. Pharmacol., 38, 805-815.
22. LEHERICY, S., HIRSCH, E.C., CERVERA-PIEROT, P., HERSH, L.B., BAKCHINE, S., PIETTE, F., DUYCKAERTS, C., HAUW, J-J., JAVOY-AGID, F. & AGID, Y. (1993). Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J. Comparative Neurology, 330, 15-31.
23. LEVEY, A.L., KITT, C.A., SIMONDS, W.F., PRICE, D.L. & BRANN, M.R. (1991). Identification and localisation of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci., 11, 3218-3226.
24. LIAO, C.F., THEMMEN, A.P., JOHO, R., BARBERIS, C., BIRNBAUMER, M. & BIRNBAUMER, L. (1989). Molecular cloning and expression of a fifth muscarinic acetylcholine receptor. J. Biol. Chem., 264, 7328-7337.
25. 1 receptors. Jr. Pharmacol. Exp. Ther., 283, 1059-1068.
26. 2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science, 228, 1115-1117.
27. NOVOTNY, E.A. & BRANN, M.R. (1989). Agonist pharmacology of cloned muscarinic receptors. Trends Pharmacol. Sci., 4 (suppl), 116.
28. 35S]thiotriphosphate) binding by eholinergic muscarinic receptors in membranes of rat olfactory bulb. J. Neurochem., 67, 2549-2556.
29. PERALTA, E.G., ASHKENAZI, A., WINSLOW, J.W., RAMACHANDRAN, J. & CAPON, D.J. (1988). Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (Lond)., 334, 434-437.
30. SAUERBERG, P., OLESEN, P.H., NIELSEN, S., TREPPENDAHL, S., SHEARDOWN, M.J., HONORE. T., MITCH, C.H., WARD, J.S., PIKE, A.J. & BYMASTER, F.P. (1992). Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J. Med. Chem., 35, 2274-2283.
31. 1B receptor antagonist with negative intrinsic activity. Br. J. Pharmacol., 125, 202-208.
32. SHANNON, H.E., BYMASTER, F.P., CALLIGARO, D.O., GREENWOOD, B., MITCH, C.H., SAWYER. B.D., WARD, J.S., WONG, D.T., OLESEN, P.H., SHEARDOWN, M.J., SWEDBERG, M.D.B., SUZDAK, P.D. & SAUERBERG, P. (1994). Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J. Pharmacol. Exp. Ther., 269, 271-281.
33. 1D receptor subtypes. J. Rec. Sig. Trans. Res., 15, 199.
34. 1Dβ receptors. Eur. J. Pharmacol., 314, 365-372.
35. WILFFERT, B., DAVIDESKO, D., DEJONGE, A., THOOLEN, M.J.M.C., TIMMERMANS, P.B.M.W.M. & VAN ZWIETEN, P.A. (1983). Role of ganglionic M1 and M2 receptors in the neuronal control of the cardiovascular system of the normotensive rat as determined with pilocarpine. Eur. J. Pharmacol., 95, 109-116.